Antineutrophil cytoplasmic antibody (ANCA) 
A b s t r a c t

Antineutrophil cytoplasmic antibody (ANCA) tests are used to diagnose and monitor inflammatory activity in the primary systemic small vessel vasculitides. ANCA is best demonstrated in these diseases by using a combination of indirect immunofluorescence (IIF) of normal peripheral blood neutrophils and enzyme-linked immunosorbent assays (ELISAs) that detect ANCA specific for proteinase 3 (PR3) or myeloperoxidase (MPO)
Antineutrophil cytoplasmic antibodies (ANCA) have been recognized for more than a decade to be important adjuncts to the diagnosis of the primary systemic small vessel vasculitides. [1] [2] [3] However, in some patients, problems
with ANCA testing or with the interpretation of the tests have resulted in incorrect diagnoses and subsequent errors in management. This is partly because new diagnostic tests often create interest before full evaluation of their clinical usefulness and specificity and sensitivity. In addition, the reproducibility of such tests is often poor until the critical technical aspects have been identified, the methods standardized, and quality control implemented. Routine laboratories may face clinical pressures to perform new diagnostic tests using commercial assays before these difficulties have been resolved.
The present article represents guidelines for ANCA testing and reporting that have been developed to minimize the technical difficulties and to produce more uniformity in the results issued by different laboratories. It was originally prepared at the request of the Australian Society of Clinical Immunologists and Allergists by immunologists from 8 Australian laboratories. The draft was circulated to each contributor and modified, and the resulting document was distributed to the 120 participants from 21 countries who attended the "ANCA and Vasculitis" symposium held as a satellite to the XIV Congress of Nephrology in Melbourne, Australia, May 30-June 1, 1997. At that meeting, the document was vigorously discussed at a 2-hour plenary session chaired by Allan Wiik. Further changes were made, and a revised version was distributed to the original contributors and to 11 experts from 3 continents who attended the meeting Savige et al / TESTING FOR ANCAS and participated in the discussion. After further revisions, the final document was returned to these persons for ratification.
Background
ANCA are autoantibodies directed against cytoplasmic constituents of neutrophils and monocytes.
1 " 3 The most common reasons for requesting an ANCA test are to diagnose and monitor activity in the primary systemic small vessel vasculitides, namely Wegener granulomatosis, microscopic polyangiitis and its renal-limited form, pauciimmune segmental necrotizing glomerulonephritis, and ChurgStrauss syndrome. [1] [2] [3] [4] [5] [6] ITable II shows the clinical manifestations that suggest the diagnosis of Wegener granulomatosis or microscopic polyangiitis and indicate that ANCA testing is warranted.
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When these clinical features are present, the demonstration of ANCA is probably 95% sensitive and 90% specific for these diseases and has a much higher positive predictive value than in other hospitalized patients. 9 The diagnosis of ChurgStrauss syndrome is suspected when asthma and eosinophilia are present in addition to vasculitis, but series are small, and the diagnostic usefulness of ANCA is less well studied. These are cytoplasmic fluorescence with central interlobular accentuation (C-ANCA), which usually occurs with PR3 specificity, 1314 and perinuclear fluorescence often with nuclear extension (P-ANCA) that occurs with MPO specificity. 315 Most patients with active generalized Wegener granulomatosis have C-ANCA with PR3 specificity, but up to 25% have P-ANCA with MPO specificity. 12 About 60%
of patients with microscopic polyangiitis or pauciimmune segmental necrotizing glomerulonephritis have P-ANCA with MPO specificity, and 30% have C-ANCA with PR3 specificity. Occasionally in these patients, C-ANCA with MPO specificity and P-ANCA with PR3 specificity occur. ANCA are less common in patients with Churg-Strauss syndrome, and the patterns and specificities resemble those found in microscopic polyangiitis. 4 Clinical definitions of
Wegener granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome do not include the demonstration of ANCA or target antigen specificity.
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In Wegener granulomatosis, microscopic polyangiitis, and pauciimmune segmental necrotizing glomerulonephritis, ANCA levels usually correlate with disease activity and are high at initial examination, decline with treatment, and increase in about 50% of the patients who experience a relapse. 7, 8 In addition, about 50% of the patients in whom antibodies recur will relapse. The results are likely to be similar in Churg-Strauss syndrome. About 10% of patients with Wegener granulomatosis, microscopic polyangiitis, or pauciimmune segmental necrotizing glomerulonephritis also have antiglomerular basement membrane antibodies. 18 Most of the neutrophil cytoplasmic fluorescence detected in a routine laboratory is not found in patients with the primary systemic small vessel vasculitides. 19 About half the cytoplasmic fluorescence is "flat" and lacks the interlobular accentuation seen with PR3-ANCA. 19 " 22 This is C-ANCA (atypical), in which the corresponding antigen specificities include MPO and bactericidal/permeability-increasing protein but are usually unknown. 21, 2324 Overall, the most common IIF pattern is a P-ANCA that lacks the nuclear fluorescence seen with many MPO-ANCA. 15 These P-ANCA occur in 50% to 70% of patients with ulcerative colitis, 28 and about 20% of patients with systemic lupus erythematosus. 29 These frequencies differ between laboratories because of cohort variation and differences in detection methods. A less common fluorescence pattern is the granulocyte-specific antinuclear antibody (ANA) seen in patients with rheumatoid arthritis and sometimes with inflammatory bowel disease 30 and that probably represents a form of P-ANCA.
Atypical ANCA is used for fluorescence patterns other than those described as C-ANCA, C-ANCA (atypical), or P-ANCA and most often is a combination of cytoplasmic and perinuclear fluorescence. Atypical ANCA occur in patients with inflammatory bowel disease, rheumatoid arthritis, and some types of drug-induced vasculitis. 31 - 32 All forms of P-ANCA and atypical ANCA fluorescence are artifactual and occur only with ethanol-fixed (and acetone-fixed) neutrophils; the same serum samples produce cytoplasmic fluorescence on formalin-fixed cells. 3 Many P-ANCA (including granulocytespecific P-ANCA) and atypical ANCA have multiple antigen specificities. These include a-enolase, 33 catalase, 34 highmobility-group nonhistone chromosomal proteins, 35 actin, 36 cathepsin G, 37 elastase, 31 lactoferrin, 38 lysozyme, 39 and other unidentified targets. 40 With ANCA in which the specificities are not PR3 or MPO, antibody levels are variable but often low, and there usually is no clear correlation with disease activity or other clinical variables.
Testing for ANCA
ANCA testing should not be performed if the following minimum requirements cannot be fulfilled. The optimum recommendations ensure the most reproducible and clinically relevant results. 
IIF Assay
Minimum
Savige et al / TESTING FOR A N C A S
I With P-ANCA, some nuclear fluorescence of lymphocytes near an IIF-positive neutrophil is noted occasionally because the fixation process results in the leakage of neutrophil cytoplasmic constituents that subsequently adhere to nearby lymphocyte nuclei. 
Reporting of IIF Results
Nomenclature
Comments I
The use of the terms C-ANCA and P-ANCA, 44 rather than cANCA and pANCA, to describe the IIF patterns conforms with the style for the descriptions of antigen specificities (eg, PR3-ANCA).
I This classification distinguishes between cytoplasmic, but not perinuclear, fluorescent patterns. This is because IIF results can be released before the ELISAs are performed, and many clinicians still mistakenly believe that all cytoplasmic fluorescence correlates with PR3 specificity and indicates a small vessel vasculitis. While it is usually easy to distinguish between different P-ANCA with and without neutrophil nuclear extension, the correlation of P-ANCA with nuclear extension and MPO specificity, and P-ANCA without nuclear extension with other antigen specificities, is less consistent than the correlation of C-ANCA with PR3 specificity and small vessel vasculitis. In addition, most clinicians are aware that P-ANCA occur in many autoimmune diseases.
Minimum
I The IIF pattern is described as C-ANCA, C-ANCA (atypical), P-ANCA, or atypical ANCA. I The report indicates that neutrophil fluorescence alone is not specific for the diagnosis of Wegener granulomatosis or microscopic polyangiitis. I The report indicates that all IIF-positive serum samples
have been or will be tested for antigen specificity by ELISAs for PR3-ANCA and MPO-ANCA.
I The report indicates when the laboratory is unable to confirm a P-ANCA because of a concomitant A N A and that ELISAs for PR3-ANCA and MPO-ANCA will be performed.
Optimum I
The fluorescence intensity is graded negative, weakly positive, or strongly positive on the basis of the screening dilution only. I The IIF results for negative serum samples are not reported until the ELISAs for PR3-ANCA and MPO-A N C A have been performed. I The report indicates whether ELISAs for A N C A specificities other than PR3 and MPO are appropriate and which specificities are available.
ELISAs
Antigens Minimum I Manufacturers supply details of the purification method and the purity of each antigen. I If PR3 and MPO are purified in house, the purification method that causes the least denaturation should be used.
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I Native antigens are preferred to recombinant antigens, whose usefulness still must be verified. 45 I Assays using new batches of commercially available or in-house purified antigen should be validated against "old" preparations.
Optimum I The purity of the antigens prepared in house should be verified in an ELISA system, with monoclonal or polyclonal antisera against potentially contaminating A N C A antigens, such as lactoferrin. I Serum samples are assayed in duplicate. I The cutoff point, even for commercial ELISAs, is verified in house. This value is calculated by using samples from hospitalized patients and set high enough to achieve more than 90% specificity for the systemic vasculitides compared with control samples from hospitalized patients. If an earlier serum sample from the patient was positive by ELISA, then antibody levels can be compared with a previously positive serum sample from the same patient by ELISA.
Assay
Minimum
Comments
IPR3 purification techniques do not substantially influence the level of binding of PR3-ANCA by ELISA.
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E A serum standard for C-ANCA with PR3 specificity is available from AW, Statens Seruminstitut, Denmark (e-mail: aw@ssi.dk).
I Subtracting the binding to antigen-free or proteincoated plates helps reduce false-positive results caused by the nonspecific binding of "sticky" serum samples.
• Nonspecific binding should be suspected if PR3-A N C A and MPO-ANCA are detected in the same serum sample at low levels.
I There are no standard units for the results from PR3-A N C A and MPO-ANCA ELISAs. I Some laboratories use rapid qualitative techniques for PR3-ANCA and MPO-ANCA, and positive results are confirmed quantitatively later.
I Some laboratories screen serum samples from patients with acute pulmonary-renal syndrome for A N C A and antiglomerular basement membrane antibodies. 46 Wegener granulomatosis and microscopic polyangiitis are more common causes of the pulmonary-renal syndrome than is antiglomerular basement membrane disease, 47 but the conditions coexist in 10% to 30% of patients. 2. C-ANCA (atypical) has no clinical significance. 3. P-ANCA with MPO specificity occur in 50% to 80% of patients with active microscopic polyangiitis (which may be confined to the kidney as segmental necrotizing glomerulonephritis) and up to 25% of patients with Wegener granulomatosis. 4-In Wegener granulomatosis and microscopic polyangiitis, A N C A levels usually decline with treatment but increase in about 50% of patients who experience a relapse; conversely, about 50% of patients in whom A N C A recur will relapse.
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Reporting of ELISA Results
Nomenclature
5. P-ANCA (usually with specificities other than MPO) occur in some patients with inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, chronic active hepatitis, and other autoimmune diseases. In these patients, A N C A levels are often low and of uncertain clinical significance.
6. Atypical A N C A (and P-ANCA) are found in some drug-induced vasculitides but are otherwise of uncertain clinical significance.
